The FDA approved bluebird bio’s gene therapy treatment for childhood cerebral ALD on September 16, 2022. Gene therapy is a treatment option for children with cerebral ALD that offers an alternative to allogenic hematopoietic stem cell transplant, eliminating the need for a bone marrow match. Bluebird bio plans to make SKYSONA® (elivaldogene autotemcel), also known as eli-cel, commercially available by the end of 2022 at designated treatment centers. Bluebird bio’s patient services program, my bluebird support, which is appropriate for both caregivers and clinicians to use, can be reached at: 1-833-888-NEST (6378) Monday–Friday, 8 am–8 pm ET or online at mybluebirdsupport.com.
Read More Here:
bluebird bio: info@bluebirdbio.com
